

BioHealth Innovation

www.biohealthinnovation.org

Founding Member





Genetic Engineering & Top 3 BioPharma Cluster

& Biotechnology News



Top 10 U.S. Biopharma Clusters 2025

Ranking Based on Five Criteria:

- 1. NIH Funding
- 2. Venture Capital Funding
- 3. Patents
- 4. Lab Space
- 5. Jobs

- 1. Boston/Cambridge, MA
- 2. San Francisco Bay Area
- 3. BioHealth Capital Region (Maryland/Virginia/DC Metro)
- 4. New York/New Jersey
- 5. San Diego
- 6. Los Angeles/Orange County, CA
- 7. Greater Philadelphia
- 8. Raleigh-Durham, NC (Inc. Research Triangle Park, NC)
- 9. Seattle
- 10.Chicagoland

#3 - 2025 BioHealth Capital Region (MD-VA-DC)

- 1st in Patents
- 3rd in NIH funding
- 3rd in Lab Space
- 4th in Jobs
- 7th in VC Funding



"The BioHealth Capital Region is home to the FDA and NIH, which have eliminated 3,500 and 1,200 jobs, respectively. Government cuts helped shrink employment 1.8%, to 133,743 jobs (JLL data), pushing the region to fourth from third. Yet BHCR stayed in third place by leading the nation in patents (79,141 families) and placing third in lab space (36.823 million square feet according to JLL, including the NIH's 9.2 million square feet in Bethesda, MD) and NIH funding (4,806 awards totaling \$3.639 billion, down 16% from a year ago). Venture capital nosedived 53%, lowering BHCR to seventh with \$1.03 billion in 2024 and \$357.18 million in Q1-Q2 2025 (also JLL data)." -Alex Philippidis, Senior Business Editor at Genetic Engineering & Biotechnology News

The Growth of the "BioHealth" Brand

- BioHealth Innovation
- BioHealth Capital Region
- Office of BioHealth Maryland Department of Commerce
- BioHealth Capital Region Genetic Engineering News
- Activation Capital's "Frontier BioHealth"
- Institute for BioHealth Innovation George Mason
- AURP BioHealth Caucus
- The Bangkok 2025 Global Biohealth Al Innovation and Traditional Medicine Fusion Cooperation Summit
- The Las Vegas BioHealth Innovation Challenge

- Wisconsin's BioHealth Industry
- Women in BioHealth U.W. Madison
- Growing BioHealth Cluster Ohio
- Luxembourg BioHealth Cluster
- South Korea BioHealth Industry
- Greece BioHealth Innovation Hub
- HIG BioHealth Fund
- BioHealth Sciences Oregon
- ibs.GRANADA BioHealth
- K•BIC Korea Biohealth Innovation & Start-up Center
- House of BioHealth Luxembourg









BioHealth Capital Region: An Overview of the BHCR - Where You Should Be



Top Tier Research Universities

Including Johns Hopkins and the University System of Maryland provide a pipeline of talent & intellectual property

- 78 National Labs & Research Institutes
 Including NIH, ARL, NRL, and NASA Goddard that receive
 \$19 billion annually and provide technical talent and a pipeline of tested, commercializable technologies
- Regulatory & Governmental Bodies
 Including FDA, CMS, and HHS provide thought leadership in the ecosystem and insight into what changes are next
- Concentration of Science & Engineering Talent
 From universities, national labs, and government positions
 with the technical skills to launch high-tech startups,
 especially with licensed intellectual property
- Established Cluster of BioHealth Companies

 Over 2,300 BioHealth companies in BHCR from

 multinational corporations to cutting edge startups

BioHealth Innovation

Challenges to Innovation Economy

Lack of connection of innovation resources

Lack of an entrepreneurial culture & C-level executives

Lack of early-stage funding for commercializing technologies

Lack of spin-offs from federal & university R&D

Solutions for the Innovation Economy

Connect regional innovation assets

Develop an entrepreneurial talent & support pipeline

Attract funding for technology commercialization

Evaluate commercially relevant federal & university technology

Regional BioHealth Ecosystem Partners

ACADEMIA

- RESEARCH/T2
- LIFELONG LEARNING
- ECONOMIC DEVELOPMENT

INDUSTRY

- PROFIT
- PROCESS
- PRODUCT

INSEPARABLE MISSIONS

GOVERNMENT

- Sustainability
- INFRASTRUCTURE SUPPORT
 - ECONOMIC POLICY

FOUNDATIONS/NGOS

- ECONOMIC GROWTH
- COMMUNITY INVESTMENT
- REGIONAL COLLABORATION



BHCR Support Organizations



BioHealth Innovation

Richard A. Bendis
President/CEO

"BHI sources and evaluates market-relevant biohealth intellectual properties, connects the IP with funding, andassists businesses in marketing and growth."





John Newby CEO

"We fuel the network of leaders that drive bioscience to eradicate disease, save lives, and feed the world.....one innovation at a time."





Kelly Schlutz CEO

"We are a collaborative community that is actively engaged in building strong technology and life science industries by supporting the efforts of our individual members."





Ron Piervincenzi , Ph.D. CEO

"It's clear global collaboration remains essential to ensuring a focus on quality that increases supply chain resilience and facilities advances in therapies and technologies."





Troy LeMaile-Stovall
CEO & Executive Director

"TEDCO provides framework of knowledge, funding, and networking to support an innovation eco-system that nurtures researchers, entrepreneurs, start-ups, and early-stage companies engaged in bringing innovation ideas to market."





Bill Thompkins President & CEO

"We are a premier destination with a powerful network of existing businesses across a wide range of industries. Our deep talent pool, diverse and vibrant communities, and proximity to the federal agencies including the Departments of Transportation and Energy, FDA, and NIH position the County's companies for success."



Johnson Johnson

Rachel Rath Head of JLABS @ Washington, DC

"At JLABS @ Washington, DC, we support early-stage life science innovators with lab space, mentorship, and access to Johnson & Johnson's network."





Joe Benevento

"VIPC is well-positioned to lead Virginia in developing, attracting, and retaining talent, capital, and innovation which expands investment, growth, and opportunity across the entire Commonwealth"

BioHealth Innovation: An Innovation Intermediary

A public-private partnership, serving as an innovation intermediary in the BioHealth Capital Region with a mission to:

- Advance local technologies, assets and resources
- Accelerate innovation
- Globally connect sectors, industries, communities, and markets



- Regionally, Nationally, and Internationally-Oriented
- Private-public partnership, 501(c)(3) nonprofit
- BioHealth Innovation Management, a for-profit subsidiary
- Market-driven, private sector-led and funded
- Neither a government initiative, nor a membership organization



BioHealth Innovation Board of Directors

Adventist HealthCare	John A, Sackett President & CEO Adventist Healthcare	Emmes	Peter Ronco CEO The Emmes Corporation	M&T Bank	Christopher Callaghan Group Vice President Healthcare Banking M&T Bank
A L E X A N D R I A _*	Joel Marcus Executive Chairman & Founder Alexandria Real Estate Equities	GM GEORGE MASON UNIVERSITY.	Amy Adams Executive Director, Institute for Biohealth Innovation George Mason University	FEDERAL CREDIT UNION	Rick Wieczorek President / Chief Executive Officer NIH Federal Credit Union
AMGEN	Yaminah Leggett-Wells Senior Director, Alliance Management AMGEN	gsk	Steven Roberts Director, External R&D Scientist Collaborations GSK	ON DEMAND PHARMACEUTICALS	Jarrod Borkat Chief Commercial and Strategy Officer On Demand Pharmaceuticals
BioHealth Innovation	Richard A. Bendis President & CEO BioHealth Innovation Inc.	(())JLL	Pete Briskman (CHAIR) Executive Managing Director Lead Mid-Atlantic Life Sciences Practice Jones Lang LaSalle (JLL)	Phlow	Eric Edwards Co-Founder & CEO Phlow Corporation
- COLIONAL	Donna Edmonds (Vice Chair) Founder & CEO Brainbox Solutions	Johnson&Johnson	Rachel Rath Head JLABS @ Washington DC	University System of Maryland	Dr. Jay Perman Chancellor University System of Maryland
Canon	Ronald Kurz Vice President, Business Development Group Canon Virginia, Inc.	J.P.Morgan	Brett Shealy Executive Director of Life Sciences J.P. Morgan	usp	Anthony Lakavage Sr. Vice President, Global External Affairs US Pharmacopeia
Deloitte.	Dr. Jessica Nadler Managing Director Deloitte Consulting, LLP	Kelly	Sarah Porter Vice President Kelly Services	VENABLE LLP	Charles Morton (Secretary) Partner Venable, LLP
EMERGENT"	Jason Hall VP, Portfolio Management Emergent BioSolutions	miRecule RAA Therapeutles	Dave Lemus (Treasurer) CFO/COO miRecule	United Therapeutics	Aimee Smart Vice President of Clinical & Regulatory Processes United Therapeutics


































BioHealth Innovation Organizational Chart




BioHealth Technology Focus

- Therapeutics
- Diagnostics
- Medical Devices
- Vaccines
- Healthcare Services
- E-Health
- Digital Health
- Electronic Medical Records
- Biomarkers and Tools
- Health Informatics
- BioHealth Cybersecurity
- Personalized Health
- Al, Machine Learning, Quantum










Innovation Paradigm Shift

PROOF OF CONCEPT
Technological Feasibility
(Laboratory Push)
"It Works!"




PROOF OF COMMERCIAL
RELEVANCE
(Market Pull)
"It Works To Solve A
Problem" "I'll Buy It"





State of Maryland: Federal & University Resources



- Population: 6.2 Million People
- 78 Federal Laboratories, Centers & Institutes in Maryland
- Maryland Federal R&D Investment Exceeding \$25 Billion Annually

JHU and USM represent another \$5 billion in annual R&D











Unrivaled Research Assets Unfulfilled Commercial Promise 800+ BioHealth Companies







































BioHealth Regional Innovation Cluster Assets





















































Major Regional BioHealth Companies































































Public BioHealth Companies Headquartered in the Region











































BIOHEALTH CAPITAL REGION Week








SEPTEMBER 23-25, 2025




BioHealth Capital Region Forum





Sponsors



2025 BHCR Week Sponsors















































Health3-2-1























































2025 BHCR Week Highlights



BHI's Rich Bendis Welcomes Attendees to the 11th Annual BHCR Week



Secretary of Commerce and Trade for the Commonwealth of Virginia Juan Pablo Segura



Matthew Keesan, Vice President and GM of Quantum Platform at IonQ giving his Day Two Keynote



William Hurley "Whurley", Founder and CEO of Strangeworks, giving his Day 1 Keynote on Quantum Computing



Rich Bendis presenting Perfusion Medical's CEO, Gerard Eldering with the 2025 BHCR Crab Trap Awards

USP CEO Ron Piervincenzi, PhD, during his Day One Fireside chat

BIOHEALTH CAPITAL REGION Week



DISTINGUISHED JUDGES:



Rich Bendis
MODERATOR
President & CEO
BioHealth Innovation, Inc.



Teddy Gresser Senior Director Seed Funds TEDCO



Conley Jones
Vice President
Alexandria Venture Investments
at Alexandria Real Estate
Equities, Inc.



John Newby Chief Executive Officer Virginia Biotechnology Association



Anthony Obi Jr.
Senior Investment Associate Virginia
Venture Partners



Esther Park
Associate Director
Blackbird Laboratories



Joseph Siletto
Co-Managing Partner, Life Sciences
J.P. Morgan

CONSIDERATIONS

- Technical Feasibility & Intellectual Property
- Commercialization & Marketing Strategy
- · Leadership Team & Collaborations
- Funding to Date & Financial Projections

CRITERIA

- Demonstrated Proof of Concept
- Have received Funding (dilutive/nondilutive)
- Understanding Regulatory/Reimbursement Paths
- · Clear Path to Market & Scalable

Crab Trap Partners:









Previous Crab Trap Winners

2025	PERFUSION	<u>Perfusion Medical</u> is developing PM-208, a therapy that restores blood flow and oxygen delivery after trauma or ischemic injury, based on Virginia Commonwealth University technology and supported by over \$10 million in federal and private funding as it advances toward clinical trials.
2024	Linshom Medical Every Breath Counts	<u>Linshom Medical</u> offers the first wearable, FDA-cleared device providing a continuous, real-time respiratory profile at the bedside, monitoring key metrics to identify respiratory decline up to 70 minutes before an emergency and improving patient outcomes.
2023	LUMINOAH	<u>Luminoah</u> is a MedTech company on a mission to revolutionize the enteral feeding market with a wearable system that combines durable medical equipment, consumable nutrition pouches, and remote patient monitoring to optimize compliance and clinical outcomes.
2022	NEUR OENE THERAPEUTICS	Neuroene Therapeutics was founded to develop a drug discovery platform for mitochondrial dysfunction diseases, with a patent portfolio covering numerous analogs.and pending patents covering hundreds of analogs aimed at the treatment of numerous disease indications and the corresponding methods.
2021	NANOCHON*	Nanochon is innovating a 3-D printed implant that replaces cartilage, fosters tissue growth, and aims to redefine cartilage restoration in healthcare.
2020	Brain Sc o pe°	BrainScope FDA-cleared portable EEG device triages head-injury patients for brain bleeds and concussions.
2019	floreo	<u>Floreo</u> uses virtual reality to teach real-world skills to individuals with autism and other developmental challenges.
2017	LIFESPROUT	<u>LifeSprout</u> develops synthetic soft tissue substitutes for aesthetic and reconstructive medicine, promoting tissue regrowth without the need for tissue transfers.
2016	SONAVEX	Sonavex, pioneers automated ultrasound technology for improved surgical outcomes, offering clinicians actionable data and cost savings

BioHealth Capital Region Serial Entrepreneurs



Mark P. Clein

- Precision for Medicine, Inc.
- United BioSource Corporation
- Infoscriber Corporation
- U.S. BioServices, Inc.



James S. Gammie, MD

- Correx, Inc.
- Harpoon Medical



Murat V. Kalayoglu

- Cartesian Therapeutics
- Topokine Therapeutics
- HealthHonors Corporation



Anthony Saleh

- miRecule
- Mimetas
- BioHealth Innovation



Rachel King

- GlycoMimetics
- NEA
- Genetic Therapy, Inc.



Ethan D. Leder

- Precision for Medicine, Inc.
- United BioSource Corporation
- U.S. BioServices, Inc.



Michael Richman

- NextCure
- Amplimmune



Martine A. Rothblatt Ph.D., J.D.

- United Therapeutics Corporation
- GeoStar
- SiriusXM Satellite Radio



Wendy Perrow

- AsclepiX Therapeutics
- Alba Therapeutics Corporation



Steve Turner

- Protea Biosciences Group, Inc.
- Clinomics BioSciences Inc.
- **Quorum Sciences**



Peter Greenleaf

- Aurinia
- Cerecor
- Sucampo
- MedImmune



Bill Enright


- · Gravitas Therapeutics Inc.
- **Barinthus Biotherapeutics**
- Avidea Technologies
- Altimmune Inc.

BHI Commercialization Model

This commercialization model shows the steps and partners that are involved in the BHI commercialization and support process.

The process below leads to the creation of new companies, spin-outs and strategic partnerships.


BHI connects companies with a network of public, private and academic entities.



NIH Partnership Agreements



NIH Consulting Entrepreneur Services Contract for NIH Entrepreneurs-in-Residence







PIA between BHI and NIH's SEED Office that supports the 27 NIH institutes and an extramural research budget of tens of billions to **promote and foster cooperative research and accelerate technology commercialization** among NIH businesses, and universities.



BHI Supports BioHealth Commercialization

BIOHEALTH INNOVATION, INC. (BHI) is a public-private, nonprofit 501(c)(3) organization focused on accelerating the commercialization of BioHealth technologies (including therapeutics, diagnostics, vaccines, medical devices, digital health, and artificial intelligence) in the BioHealth Capital Region (MD, DC, VA), US, and globally. BHI and its team of experienced EIRs have supported universities, entrepreneurs, and government agencies to accelerate biohealth technology commercialization.

ENTREPRENEUR-IN-RESIDENCE (EIR) CAPABILITIES - Over the past decade, BioHealth Innovation has developed a pool of committed and experienced BHI executives capable of supporting every need of a life science company, entrepreneur, academic researcher, or a government-funded project, including:

- Fractional CXO Support
- Fundraising Strategy
- Pitching Coaching
- Go-To-Market Strategy
- Business Development
- International Soft-Landing
- US Marketing Entry Strategy
- Partner/Deal Sourcing

- Regulatory Strategy
- Clinical Plan Development
- Reimbursement Strategy
- Intellectual Property Support
- Strategic Partner/KOL Identification
- Quality Support
- Health Economic & Outcomes

- Health Economic & Outcomes Research (HEOR)
- Development of Value Proposition(s)
- Product Differentiation
- Cybersecurity
- Artificial Intelligence (AI)

ANALYST TEAM CAPABILITIES:

Secondary & Primary Market Research • Market Validation • Competitive Analysis • Grant Mapping/Non-Dilutive Funding Support



Montgomery County Executives in Residence

Montgomery County is funding BHI's work as part of its mission to grow the local life sciences cluster

Launched in November 2022 – inspired by BHI's well-regarded NIH program, which features over a dozen experts in various disciplines, embedded within different institutes.

Goal is to provide impactful, life-sciences-specific services to a few local companies, opposed to general

business assistance to many.

"MoCo" EIRs may provide:

- Technology validation
- Assistance with customer discovery
- Regulatory and reimbursement strategies
- Market assessment
- Non-dilutive funding assistance
- Other assistance to launch and/or advance the business.

Montgomery County is also **funding** assistance from specialized experts, attorneys, and regulatory experts that cannot be provides by EIRs



Luis Gutierrez Kevin Heller





Jonathan Kay



Ien Butler





Albine Martin Deanne Randolph

Steve Wolpe

Any early or growth-stage BioHealth company headquartered in Montgomery County may be eligible for free assistance


Exclusive BHI EIR Partnership with ARPA-H

BHI signed a PIA agreement with the ARPA-H, a \$1.5 Billion HHS Institute, to provide EIRs to their performers

- BHI is providing part-time EIRs to ARPA-H funded Performers and Program Managers which started December 2023.
- **2. Strategic Collaboration:** BHI and ARPA-H have joined forces to enhance the development and commercialization of innovative health solutions.
- 3. Entrepreneurs-in-Residence (EIRs): BHI will provide EIRs with strategic guidance to ARPA-H Program Managers in crucial areas such as technology development, intellectual property, and small business needs.
- **4. Bridge to Market Realization:** The partnership aims to bridge the gap between innovation and market realization, ensuring that transformative health solutions reach those who need them most.
- 5. Embedded Support: EIRs will provide embedded support to ARPA-H funded performers, assisting in business plan development, commercialization strategy, market research, and more.
- **6. Transition to Market:** EIRs will actively contribute to the transition of ARPA-H funded solutions into the market and identify new programs aligned with ARPA-H's primary mission.
- 7. Learn More: To explore this exciting collaboration further, read full announcement.



Innovation Capital Valley of Death





Meet Our Team BioHealth Innovation



Rich Bendis President & CEO





Lynne Brisbane VP Finance, HR, Operations



Jem Haskin Finance, HR, Operations



Jon Nelson Manager of Client Engagement



Kelly Murphy Life Science **Business** Strategist/Program Manager



Mona Suliman Life Science **Business Strategist**



Catherine Leasure Life Sciences Business Communications & Strategist



Andy Eckert Marketing



JT Koffenberger IT/Systems

Entrepreneurs in Residence



Renée JG Arnold ARPA-H EIR



Ray Blanchard ARPA-H EIR



Charles Buchen NIH/NIA/EIR



Todd Buck ARPA-H EIR



Jennifer Butler Executive in Residence



Joseph DiCesare ARPA-H EIR



Jessica Foley ARPA-H EIR



Marcella Garcia APRA-H EIR



Luis T. Gutierrez Executive in Residence



Kevin Heller Executive in Residence



Diane Ignar NIH/NHLBI/SEED ARPA-H EIR



Executive in Residence





ARPA-H EIR









ARPA-H EIR







Deanne Randolph Executive in

Residence



John Reinhart



ARPA-H EIR



Ethel Rubin NIH/OER/EIR







ARPH-A EIR










NIH Seed/ EIR





BioHealth Innovation EIRs & Strategists Team



BHI Federal Funding Assistance

- \$5 billion annual United States Government program coordinated by the Small Business Administration provides grants or contracts to small businesses to spur technological innovation
- Grants awarded in 3 phases between \$150,000 and \$4.0 million
- Non-dilutive





BHI SBIR/STTR Assistance Program Overview

BioHealth Innovation, Inc. (BHI) is a leader in providing SBIR/STTR assistance to growth stage companies ready to advance their healthcare initiatives and commercialize new technologies. BHI works with our clients from beginning-to-end to provide a customizable experience dependent on their specific needs.

BHI boasts a **3x** win rate compared to the national average!

SERVICES OFFERED

Full Development Program

BHI provides in-depth help throughout the entire writing, submission, and resubmission process. This includes (but is not limited to) strategizing, crafting specific aims and overall narrative, managing communication with program officers, developing the budget, and drafting components of the grant.

This program is project-based, not hourly-based.

Targeted Development Program

BHI commits to 10-20 hours providing feedback and general advice, editing research and commercialization plans, reviewing the budget, assisting with grant administration and rules, and advising on general strategy.

Grant Mapping

Whether you possess grant writing skills or not, identifying the right funding opportunity for your specific goals and situation can be challenging. BHI helps support companies in finding non-dilutive funding through federal and non-government organizations to fuel your success, delivering options tailored to your unique circumstances.



BHI Commercialization Support

Market Research

Our comprehensive market research service empowers life science companies to make informed decisions as they bring their innovations to market. We conduct in-depth analyses of industry trends, competitor landscapes, and potential customer segments to identify lucrative opportunities and potential challenges. Our expert team utilizes cutting-edge research methodologies to gather actionable insights, helping you refine your value proposition, optimize your go-to-market strategy, and maximize your technology's commercial potential. With our tailored market research, you'll gain the knowledge and confidence to navigate the complex life sciences marketplace effectively.

Maryland Innovation Initiative - Commercialization Support

We provide expert guidance throughout the commercialization process, helping awardees transform their groundbreaking research into market-ready products. Our services include refining business strategies, conducting targeted market research, and developing compelling investor presentations. By leveraging our industry expertise and extensive network, we enable MII recipients to navigate the complex path from lab to market, significantly enhancing their chances of commercial success and accelerating the timeline to market entry.



University Commercialization Support







GEORGETOWN UNIVERSITY



University of California San Francisco









INTERNATIONAL COLLABORATION: BHI'S 3-YEAR MENTORSHIP PROGRAM FOR 15 KOREAN COMPANIES

BHI-KOSME US Market Entry Program

To create a viable strategy for international expansion by understanding the competitive landscape in the US, clarifying a company's value proposition, identifying new target markets, and refining the business model.

KOSME is a Korean-government-funded non-profit created over forty years ago to support small and medium enterprises in Korea.

In 2021, 2022, and 2023, cohorts of five Korean companies participated in a 12 to 20-week BHI program to accelerate their entrance into the US.

The cohorts:

- Attended virtual lectures from subject matter experts,
- Received 1:1 and group mentoring from BHI's EIRs,
- Completed assignments, presentations and milestones;
- · Connected with strategic US partners and relevant networks; and
- Participated in the annual BioHealth Capital Region Forum and the Crab Trap pitch competition.













BHI International Soft-Landing Program

- U.S Subsidiary/Corporation Creation
- Business Development and Market Analysis
- Grant Funding/Non-Dilutive Funding Assistance
- Human Resource and General Administration Support
- Marketing and Promotion
- Pricing and Reimbursement
- Regulatory
- Resource Identification





International Company Requirements for U.S. Non-Dilutive Funding


- Company must be 51% controlled and owned by Americans
- Board of Directors must be controlled by Americans
- Most of the funded research must be performed in America

How to qualify:

- Form a U.S. Controlled subsidiary with trusted partners
- Create exclusive cross license agreement between new sub and parent for any new IP and technology created under grant funding
- Hire new U.S. management to manage new subsidiary or form partnership with a U.S. entity like BHI to manage
- Engage U.S. law firm familiar with above structures



BHI International Soft-Landing



BioTalk with Rich Bendis

BioTalk with Rich Bendis" is a BioHealth leading podcast featuring conversations with Bio and Healthcare Industry leaders. For the past 7 years, with 160+ episodes and over 50,000 downloads, Rich Bendis, Founder, President, and CEO of BioHealth Innovation Inc. (BHI) and host of BioTalk, has provided a platform for guests to discuss and share their views on the most important topics and developments happening today in the BioHealth industry.



The BioTalk podcast is featured on leading podcast platforms, including:



Apple Podcasts









Showcasing leading and emerging BioHealth hubs, including Boston, San Francisco, NYC, BioHealth Capital Region, San Diego, RTP, Seattle, Texas, and Canada.

Previous Guests Include:

- **Joel S. Marcus**, Executive Chairman & Founder, Alexandria Real Estate Equities, Inc.
- **Peter S. Briskman**, Executive Managing Director, Brokerage, Jones Lang LaSalle IP, Inc. (JLL)
- **Anthony S. Fauci, M.D.**, Former Director of the National Institute of Allergy and Infectious Diseases (NIAID)
- Ron Piervincenzi, Ph.D., CEO of United States Pharmacopeia (USP)
- Jay A. Perman, MD, Chancellor, University System of Maryland (USM)
- Mr. Hakdo Kim, President, Korea SMEs & Startups Agency (KOSME)
- Peter Ronco, CEO, Emmes

- Dr. Eric Edwards, CEO, Phlow Corp
- Alex Philippidis, Senior News Editor, Genetic Engineering and Biotechnology News
- **Gary Disbrow, Ph.D.**, Director of the Biomedical Advanced Research and Development Authority (BARDA)
- Anthony D. Saleh, Ph.D., CEO, miRecule
- Paul Vulto & Jos Joore, Co-Founders, Mimetas
- Joey R. Hood, U.S. Ambassador to the Republic of Tunisia
- Michelle Tarver, M.D., Deputy Center Director, Chief Transformation Officer
- Center for Devices and Radiological Health (CDRH), US Food and Drug Administration



Website, News & More



BHI Website

The BHI website has news, an events calendar, research publications, regional organization feature stories and resources for the biohealth industry.

www.biohealthinnovation.org



BHI News

and feature stories.

BHI's weekly e-newsletter highlights

the Central Maryland region's news

https://biohealthinnovation.org/newsletter-archives/

articles, national biohealth trends

Struggling with SBIR/STTR applications?



BioTalk

Rich Bendis, hosts BioTalk — conversations with some of the most accomplished and exciting business, academic, and government leaders in the biohealth industry.

https://biohealthinnovation.org/biotalk-podcast/



BHI Contact

1 Church Street, Suite 801 Rockville, MD 20850 301-637-7950

info@biohealthinnovation.org www.biohealthinnovation.org



